Samsung Biologics Co Ltd operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Samsung Biologics Co Ltd with three other
pharmaceutical manufacturers in Asia:
Hualan Biological Engineering Inc
sales of 2.37 billion Chinese Renmimbi [US$345.37 million]
of which 88%
was Blood Product),
Tonghua Dongbao Medicines Company Limited
(2.54 billion Chinese Renmimbi [US$370.64 million]
of which 89%
was Pharmaceutical), and
China Biologic Products Holdings Inc
based in China
(2.49 billion Chinese Renmimbi [US$363.82 million]
of which 100%
was Human Blood Product).